White Falcon Capital Management, an investment fund manager, released its first-quarter 2025 investor letter. A copy of the ...

MADRID (Reuters) -Shares in Spanish pharmaceutical company Grifols rose on Wednesday after Canadian fund Brookfield said it was talking with shareholders, following a report from website El ...

Despite the market punishing Grifols, we believe that this presents a buying opportunity. Click here for our investment ...

The family that owns Spanish drugmaker Grifols and private equity firm Brookfield are considering whether to take the company private in a deal that could be worth around €5.5 billion (almost $6 ...

The Grifols family has held "very preliminary talks" through several investment firms over a potential takeover bid, according to a source close to the pharmaceutical company's reference shareholders.

Private equity company Brookfield has reportedly moved closer to taking control of Grifols, after months of disruption at the Spanish pharma company. A report in Spanish newspaper El Confidencial ...

Canadian investment fund Brookfield (NYSE:BAM) resumed talks on a potential takeover of Spanish pharmaceuticals company Grifols (NASDAQ:GRFS), El Confidencial reported on Wednesday, citing ...

Pursuant to the provisions of Article 227 of Law 6/2023 of March 17, on Securities Markets and Investment Services, Grifols (GRFS ... Partners Limited, the Company informs that its Board of ...

Shares in Spanish pharmaceutical company Grifols rose on Wednesday after Canadian fund Brookfield said it was talking with shareholders, following a report from website El Confidencial that it was ...

Grifols, S.A. (NASDAQ:GRFS) is a plasma therapeutic company. The one-month return of Grifols, S.A. (NASDAQ:GRFS) was 1.41%, and its shares gained 11.27% of their value over the last 52 weeks.